NovCK
Pipeline
NovCK
Program Target
Cytokine Release Syndrome
Development Stage
Research
NovMetaHealth researches and develops NovCK, a new substance-based cytokine inhibitor.
NovMetaHealth is researching NovCK, a new substance-based cytokine inhibitor and it is expected to be able to treat Cytokine Release Syndrome. Which is caused by various infectious diseases including COVID-19.
N20 effect: poly I:C medication-induced BMBM activation model
N20 reducing cytokine release
NovCK Development Status
01
Clinical Development Status
02
Patent Application and Registration Status
| Patents | IP Protection | ||||
|---|---|---|---|---|---|
| Cytokine inhibition patent (US) |
Application
2020
|
|
|
Patent expiration (expected) year
(2040)
|
|